Urinary carcinoembryonic antigen (CEA)-like molecules and urothelial malignancy: a clinical appraisal. by Coombers, G. B. et al.
Br. J. Cancer (1975) 31, 135
URINARY CARCINOEMBRYONIC ANTIGEN (CEA)-LIKE
MOLECULES AND UROTHELIAL MALIGNANCY:
A CLINICAL APPRAISAL
G. B. COOMBES, R. R. HALL*, D. J. R. LAURENCE
AND A. Al. NEVILLE
Fromn the Division of P'athology, Institute of Cancer Research, Royal Cancer Hospital,
Chester Beatty Research Institute, Fulham Road, London, SW3 6JBI
Received IS September 1974. Accepted 2 October 1974
Summary.-A total of 190 patients being treated or followed up for urothelial
carcinoma have been studied by the serial estimation of their urinary and plasma
CEA levels. Only 46% of patients with a urothelial neoplasm present have a raised
urinary CEA level. Infection or ileal conduit urine vitiate the result as they produce
high CEA levels in the urine in the absence of any neoplastic disease. The accuracy
of urinary CEA estimations is compared with that of cytology. Plasma CEA levels
do not serve as a useful guide to the presence of extra-urinary tract tumour spread
if taken as isolated readings. However, serial plasma CEA estimations may indicate
that metastatic disease is present several months before its detection by the more
usual clinical methods in a minority of patients.
THE ONCOFOETAL antigen discovered by
Gold and Freedman (1965a, b) and called
the carcinoembryonic antigen, was initi-
ally considered to occur in raised amounts
in the plasma, only in association with
endodermally derived carcinomata (Thom-
son et al., 1969). Further studies, how-
ever, have shown that raised levels also
occur in association with a wide variety
of malignant tumours of different histo-
genesis, including urothelial carcinomata,
together with some benign inflammatory
and regenerative disorders (reviewed by
Laurence and Neville, 1972). It was the
endodermal concept, none the less, which
led Hall and his associates (1972, 1973)
to examine the urine for the presence
of CEA and to find raised levels in
conjunction with urothelial carcinomata.
The present report is an extension
of this initial work. It is a prospective
surveillance study of patients with, or
who have had, proven urothelial car-
cinoma and who have been attending
the Department of Urology, The Royal
Marsden Hospital, from September 1971
to April 1974. It was aimed at assessing
the role of urinary and plasma CEA
assays as a means of monitoring the
local and distant progress of their disease.
PATIENTS AND METHODS
The principal members of the study
group are 190 patients (134 males and 56
females) who either had, or had had in the
past, histologically proven urothelial carcino-
mata. Sixty-two per cent have been assessed
for a period exceeding 12 months, and up to
24 months or over. Of the group, 47
(33 males and 14 females) either had pre-
viously undergone cystectomy and ileal
conduit diversion when first included in the
study, or underwent this procedure during
their period of observation. This high
figure (22%) reflects the greater proportion
of advanced disease seen at the Royal
Marsden Hospital.
Twenty-nine patients died during the
trial, and post-mortem confirmation of the
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TABLE I.-Urinary CEA Levels, Urothelial Carcinoma and Urinary Infection
Disease status
Tumour present, all patients
Tumour present, infection absent
Tumour absent, infection absent
No tumour ever, infection present
Ileal conduit urine
No. of
patients*
106
86
64
10
47
No. of
observations
187
138
133
29
60
Urinary CEA ng/ml
<35 35-60 61-100 > 100
79 18 21 69
74 14 17 33
112 7 5 9
2 1 6 20
4 0 1 55
Accuracy
(%)t
58
46
84
7
7
* Individual patients may appear in more than one group at different times.
t i.e. Raised levels (> 35 ng/ml) with tumour: Normal levels (< 35 ng/ml) without tumour.
extent of their disease has been obtained
whenever possible.
In addition, a further 29 patients (19
males and 10 females) who presented with
haematuria and attended a special clinic for
such patients at the Royal Marsden Hospital
have been included. None was found to
have demonstrable malignant disease. Single
observations only were obtained in this
group.
At each initial attendance, the following
investigations were performed: urinary and
plasma CEA estimation, midstream urine
for bacteriological examination, terminal
urine for cytology, together with chest
X-ray, intravenous pyelography and cysto-
urethroscopy with abimanual pelvic examina-
tion under general anaesthesia. Any addi-
tional investigations were carried out at
the discretion of the clinician. At follow-up
attendance, the same series of investigations
was performed, except the radiology, which
was repeated as clinically necessary.
Urine and plasma were collected and
assayed for CEA-like activity as described
in detail previously (Hall et al., 1972;
Laurence et at., 1972). For urinary CEA,
a midstream sample of at least 5 ml was
obtained usually on the same day, but
before, a routine check cystoscopy. For
plasma CEA, 10 ml of venous blood was
collected into a tube with 12 mg tripotassium
EDTA. The normal range of urinary CEA
is taken as < 35 ng/ml (Hall et al., 1972),
and for plasma CEA, < 12-5 ng/ml (Laurence
et al., 1972). On the basis of our experience,
plasma levels in excess of 40 ng/ml have
been taken to indicate a high level of suspi-
cion of disseminated urothelial malignant
disease. Values between 13 and 40 ng/ml
can arise with a variety of miscellaneous
infla-m-matory and regenerative conditions
(Laurence and Neville, 1972).
In the survey tumours have been assessed
using the UICC system of classification.
Evidence of dissemination has been accepted
from biopsy proven metastases, and from
radiological evidence of pulmonary, bone
or lymph node deposits.
RESULTS
Raised (> 35 ng/ml) levels of CEA
are detected in the urine of 58% of the
patients. If, however, those with urinary
infection (> 10 WBC/mm3 + > 1 x 105
pathogenic microorganisms/mm3) are ex-
cluded, only 46% show raised values
(Table I). In the presence of tumour,
the urinary CEA levels can fluctuate.
If the level exceeds 100 ng/ml, normal
levels are not observed serially or at
different times of the day. However, if
the values are minimally raised, e.g.
40-50 ng/ml, such patients may give
normal values on occasions.
The presence of infection can vitiate
the validity of the assay. Of 29 patients
with urinary infection and no demon-
strable tumour, 93% had raised urinary
CEA levels (Table I). Ileal conduit urine
also yields elevated levels of CEA, which
precludes its use to assess the presence
of further disease in the remaining
urinary tract ofsuch patients.
All the patients in Table I without
demonstrable tumour at the time of
sampling were assessed by intravenous
pyelography, cystourethroscopy and urin-
ary cytology. In the absence of infec-
tion, 84% of this group had normal
results. Sixteen per cent have raised
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of uin(letected tumotur or a resolving
infection under treatment which might
fail to yield organisms in culture. Of
this 16%, 9 isolated observations in 9
different patients showed a urinary CEA
level in excess of 100 ng/ml. Their
cytology was negative at the time of
sampling. Two later developed demon-
strable ttumours, 6 had marked pyuria
but with no organisms isolated on culture
and so may well have had an infection,
or resolving infection, not fully identified.
One patient has remained tumour-free
and his urine was unequivocally free of
infection. This urinary CEA level, how-
ever, has been found to have returned
within the normal range on 3 subsequent
occasions.
Tumours were classified according to
UICC criteria. No correlation was found
between the classification of a tumour
and the urinary CEA levels, i.e. the
more locally advanced tumours were not
necessarily associated with higher CEA
levels and vice versa. Fifty per cent of
patients with TIS and TI tumours were
found to have raised levels, compared
with 5500 for the combined heavily
invasive T2-T4 tumours.
The cytology results in this suirvey
are recorded in Table II. It was usual
TABLE II.-Urinar-y Cytology
Urothelial
carcinoma*
I'resenit
Absent
Cytology+
NO. of Posi- Nega
p)atientst tive tive
104 III 98
120 222- 302
Accutracy
(0)
53
93
* Confirmed by cystoscopyv.
t Patienits may be inclutlded( in both categories at
dlifferent times.
I There were 44 eq({ivocal reports.
for only a single terminal stream sample
of urine to be submitted for cytological
examination, but where more than one
urine sample, or bladder washings were
obtained at cystoscopy, they have been
included as only a single observation for
that particuilar assessment. Where the
several results show disagreement, the
observation has been recorded as positive
as one sample showed unequivocal malig-
nant cells. Where no tumour is believed
to be present, and cytology shows un-
equivocally malignant cells, then this
has been included as a false positive only
when the whole context of the patient's
disease, including the absence of demon-
strable tumour at the next 2 subsequent
examinations, has been assessed and it
was still believed that it was highly
unlikely that a tumour was present.
The outcome of combining the urinary
CEA and cytology results is shown in
Table III. If both are positive, then
TABLE III. The Assessment of Urothelial
Carcinomata by (Ctombined Urinary Cyto-
logy and CEA Assay
Cytology
P'ositive
Negative
Positive
Negative
Urinary
Raise(d
Normal
Normal
Raise(d
No. of observationls
with tumour
Priesent Absent
30 1
34 126
29 12
46 52
Accuracy
( /0)
96
79
* All observations free fr om iinfectioni.
a 9600 accuracy can be achieved. The
one patient with the single dissenting
observation is considered highly unlikely
to have a tumour present. Since that
observation, he has been followed up for
over one year and during that period,
his cytology has returned to and re-
mained normal and no tumours have
been found oIn cystoscopy or intravenous
pyelography. However, his urinary CEA
level continues to fluctuate above and
below the upper limit of normal. A 790o
accuracy, i.e. normal urinary CEA levels
ancd negative cytology, is attained in
subjects with no overt ttumour (Table III).
The resuilts of plasma CEA assays in
sutbjects with pre3ont or previous uro-
thelial disease are shown in Table IV.
They mav be divided into 3 groups.
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9, 300 at
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.on
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MONTHS
15 20
FIG. 1. Male. l.o.b. 27. 7. 10, presented in September 1971, i.e. zero months, with a large
suiperficial transitional cell carcinoma which progressed rapidlly to become deeply infiltrating and
pro(lu1cing an extravesical mass; treated by radiotherapy. He died 21 months after the com-
mencement, of plasma CEA monitoring, 3 weeks after the first clinical evidence of disseminated
ttumour. Autopsy findings: carcinoma of the bladder with extensive vertebral and abdominal
lymph niodle deposits.
TABLE I. IDisease Status and Plasmia CEA Levels
Disease statuts
WVell. No evi(dence of
urothelial carciinoma
Local urothelial carcinoma
Disseminated urothelial
carcinoma
Total
no. of
patients
90
Total
no. of
obs.
458
Pla,sma CEA ng/ml
13 13-20 % 21-40 40
254 55 150 33 42 9 12 3
76 228 137 60 61 27 9 8 13 6
33 73 39 53 19 26 4 6 11 15
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CXR, skull,
L/S spine,
1rlp vi .; X-rnv.q -'VP
Died
carcinomatosis
F3/7/73
5 10 15
MONTHS
Fi(e. 2. Aiale. (d.n.b. 6.9.18, piesented in January 1968 with a T3NO bla(dder carcinoma treated
by radiotherapy before radical cystectomy. By April 1973, the ninth month of CEA monitoring,
an abdomino-pelvic recurrence developed and involved the ileal conduit, necessitating a laparo-
tomy. Biopsy confirmed poorlv differentiated transitional cell carcinoma. He died 13 months
after the start of CEA monitoring, with no other evidence of recurrent, disease, despite full clinical
surveillance. The autopsy confirmed the intra-abdominal mass, plus metastases in head of
pancreas and para-aortic nodles.
E 40-
CN c
30
< 20-
< 10-
Q-
n
Pelvic node Pulmonary Died
lbiopsy +ve metastases carcinomatosis
Il, f t 1, *19/11/73
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Fie,. 3. Female. (Lo.b. 27. 10 00, presented in January 1972 with ain iniitially superficial transi-
tional cell carcinoma, which subsequently became infiltrating. Treated with gold grains in
September 1972, zero months, at which time the tumour was classifiedl as P2NI. This was there-
fore followed up with external radiotherapy. She died 13 months later and pulmonary metastases
NN,ere detected for the first time one month previously.
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Lymphogram
+ve
Metastases in Metastases in
spine, ribs iliac-crest
chest (lungs) marrow
A
,Died
/ y ;~~~~~~13/4/73 '
1 2 3
MONTHS
4 5 6
FIG.. 4.--Male. d.o.b. 1 09, presente(l in 1963 with superficial bladder tumours. In November
1972, zero months, a T3N1 tumotur was treated by radiotherapy; 2A months before death, a tumour
was found in ribs, lumbo-sacral spine, and lung fields; 1 month before death, tumour cells were
fcun(l in an iliac crest bone marrow Liopsy.
urothelial carcinoma or who have in the
past had a low-grade, non-invasive tumour
which has been destroyed so that no
demonstrable tumour remains and the
urinary cytology is consistently normal.
Also included in this group are the
post-operative results from patients who
have had a cystectomy for localized
disease, the regional nodes being free of
tumour at operation and in whom no
evidence of tumour dissemination has
been found either at the time of operation
or subsequently. Second, patients with
localized urothelial carcinomata, all of
whom had low-grade, non-invasive tu-
mours present at the time the blood sample
was taken. Third, patients with dis-
seminated disease who had this confirmed
either by biopsy of accessible metastases
or by radiological demonstration of pul-
monary, bone or lymph node deposits.
All 3 groups of patients had a similar
proportion (50-60%) of their plasma
CEA levels within the normal range
(< 12 5 ng/ml) with a further 30-40o
in the equivocal range (13-40 ng/ml).
However, serial estimation of plasma
CEA levels in individual patients at
successive hospital attendances over a
period of several months can in some,
but not all, patients yield useful informa-
tion and foretell the development of
metastatic disease by up to 12 months.
Figures 1-4 are examples of the type of
results we have obtained.
DISCUSSION
This study was directed towards
answering the following questions: (1) Is
the assay of urinary CEA, or CEA-like
material, useful in assisting with the
diagnosis of urothelial carcinomata? How
does it compare with urinary cytology
and will it enhance, either alone or in
conjunction with cytology, the successful
screening of patients for the presence
of urothelial carcinoma? (2) Is the assay
of plasma CEA a useful indicator of the
presence of extra-urinary tract spread
of urothelial cancer?
The present results seem to negate
the use of urinary CEA assays, as per-
formed at present, as an aid to the
diagnosis of this disease. Raised urinary
CEA levels (> 35 ng/ml) occur in 58% of
patients with urothelial carcinomata pre-
sent at the time the sample was taken,
compared with 53oo for urinary cytology
under the same conditions. Infection in
our, and other, series varies between
26% and 40%0 of samples (Table I;
= 507
C 40-
i5 30-
20-
LI)
-J
0L 10-
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Schoonees et al., 1 971) and vitiates the
use of urinary CEA.
When all infected samples are ex-
cluded, raised urinary CEA levels are
found in only 46% of patients with
tumours, a figure comparable with that
previously reported by Neville et al.
(1973). Hence, the eradication of infec-
tion before urinary CEA estimation is
essential. This is not always clinically
possible due to the presence of necrotic
tumour, slough, severe radiotherapy
changes or residual urine.
Cytological diagnosis, although ham-
pered by severe infection with gross
pyuria, is not totally negated by lesser
degrees of inflammation which may in-
validate the urinary CEA result. Foot
et al. (1958) had a correct positive cyto-
logical diagnosis in 61.7% of all urothelial
tumours, rising to 77.50% of vesical
lesions. Schoonees et al. (1971) had a
correct positive cytological diagnosis in
70.2% despite an infection rate of 4000.
These figures refer to the examination
of a single urine sample only but in
both cases an early morning sample was
always used. One of the reasons for
our lower diagnostic success rate is that
all the urological clinics at the Royal
Marsden Hospital are held in the after-
noons and so the benefit of overnight
urine, exposed to the tumour for 10-12 h,
was not available. We were forced to
use urine which had been in the bladder
for very much shorter periods for the
majority of examinations. Therefore, if
the system of urine collection were to
be changed and a cytological accuracy
comparable with Schoonees et al. (1971)
were achieved, then the 4600 urinary
CEA diagnostic accuracy would be placed
in its proper perspective.
We are able to confirm the original
observation of Hall et al. (1972) that
there appears to be no useful correlation
between the UICC classification of a
tumour and the urinary CEA level.
However, although the results for TIS
and TI tumours combined are marginally
better than those reported by Neville et
al. (1973), the incidence of true positive
results is comparable with that obtaine(d
in the much larger group of unclassified,
uninfected samples (Table I).
The plasma CEA value (Table IV)
appears to show no correlation with
the stage of the disease. Patients with
no known disease and patients with
disseminated disease both had over 5000
of their samples within the normal range
(< 12 5 ng/ml). This is at variance with
the previously reported findings of Hall et
al. (1972) and Neville et al. (1973), who
stated that in the presence of extra-
vesical spread raised plasma levels were
found in 85% of patients. Our present
numbers of patients are larger than in
the previous series and are therefore
probably a more accurate reflection of
the true situation. While isolated plasma
CEA levels are of little value, their serial
estimation can help to detect metastatic
disease before other clinical methods
(Fig. 1, 2). While considerable benefit
may have accrued to these patients,
negative results as shown in Fig. 3, 4
were more commonly encountered. The
sequential analysis of plasma CEA levels
may therefore have a useful contribution
to make in the follow up of patients with
urothelial carcinoma, but we are unable
at present to indicate which patients
will show a rise with tumour dissemination
and which will not.
In the urine, CEA, as detected by
the radioimmunoassay, exists as a wide
variety of molecular species varying in
molecular weight from 1 x 103 to 2 x 107
(Nery et al., 1974) and so is better referred
to as " CEA-like ". There are three
principal and distinct substances desig-
nated UCEA-1, UCEA-2, UCEA-3 (Nery
et al., 1974; Neville et al., 1973). UCEA-3
is a large macromolecule; UCEA-2 has
a molecular weight of the order of 60,000
and its probably related to CCEA (colonic
CEA)-2, or CEX (Darcy, Turberville and
James, 1973; Turberville, et al., 1973).
UCEA-1 has a molecular weight of the
order of 200,000 and is similar to CEA
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cinomata (Turberville et al., 1973; Nery
et al., 1974). The routine radioimmu-
noassay for urinary CEA utilized reagents
prepared from colorectal carcinomata
and measures the total CEA-like activity
in the sample. These preliminary obser-
vations tend to suggest that urinary CEA
is probably chemically distinct from CEA
of colonic origin. Hence, work is under
way to extract the appropriate tumour
antigen from urothelial carcinomata which
also occurs in the urine, and to develop
an assay to this material specifically
rather than use the cross-reacting systems
as at present.
In view of this, it would appear that
the current method of assaying CEA or
" CEA-like " materials in both urine and
plasma of patients with urothelial neo-
plasia is not reliable enough to justify its
present clinical use.
Inference
This study has analysed the levels
of CEA-like materials in the urine and
plasma of 190 patients with urothelial
carcinomata. Due to the low specificity
of the assay for urinary CEA and the
occurrence of false positive rises in the
presence of infection, its clinical usage is
vitiated at this time. However, in a
number of patients the serial assay of
plasma CEA can foretell the develop-
ment of disseminated disease by up to
12 months. Efforts are being made to
improve the sensitivity and specificity
of the assay so that useful clinical results
may be obtained.
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